Jump to content

Biomedical Technology

EU Funded

Graphene for healthcare applications 

As the demand for healthcare services continues to increase, so does the demand for novel healthcare solutions. These solutions should be more effective, cost less, prevent and cure disease, and should be equally effective throughout the world. Graphene is paving the way for novel diagnosis and treatments, thanks to its unique properties, such as high surface area, electron mobility, and functionalisation potential; all favourable for biomedical technologies.

For instance, the surface area of graphene makes an excellent platform for drug delivery and the conductivity makes for effective biosensors. The ability of graphene to be made into scaffolds whilst maintaining the inherent conductivity can be put to use in tissue engineering. New research has shown that graphene can be incorporated with a polymer to make very sensitive electromechanical sensors, and that it can be used to make improved deep brain implants.

The most advanced and promising areas in the biomedical field are currently those where graphene is used in a device configuration. For example, in Point-of-Care or In Vitro diagnostics, graphene can be used as a sensor and be duly functionalized to tune its sensing capabilities. Graphene-based neural interfaces have also demonstrated the possibility to not only detect wavelengths in the brain that cannot be detected with current metal-based technologies, but also to stimulate the tissue, opening up possibilities for new therapies.

​Cinzia Spinato, Business Developer for biomedical applications for the Graphene Flagship

Graphene Biomedical Products

From graphene-based retinal implants to robotic prosthetic hands controlled by wearable sensors made by cellulose and graphene composites. Graphene Flagship researchers are using graphene to expand the realm of possibility within the biomedical sector.

The latest on Biomedical Technology

artificial retina
Biomedical / Innovation / Milestones

Graphene oxide added to the composition of the liquid artificial retina: A further step toward clinical trials


Graphene Flagship partner, the Istituto Italiano di Tecnologia, together with IRCCS Azienda Ospedaliera Metropolitana – Policlinico San Martino Hospital, has demonstrated that graphene oxide—used for the first time in the ophthalmic field—enhances the liquid artificial retina, increasing light sensitivity and recovery of visual function in advanced stages of retinitis pigmentosa. The study, published in Nature Communications, led to the restoration of electrical activity in the visual cortex, bringing this strategy closer to future clinical trials in humans.

By Graphene Flagship / 13 May 2026
Show all news